28410411|t|Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3
28410411|a|Hepatitis C virus (HCV) infection is characterized by a high frequency of chronic cases owing to the impairment of innate and adaptive immune responses. The modulation of natural killer (NK) cell functions by HCV leads to an impaired innate immune response. However, the underling mechanisms and roles of HCV proteins in this immune evasion are controversial, especially in the early phase of HCV infection. To investigate the role of HCV nonstructural proteins especially NS3 in the impairment of NK functions, NK cells were isolated from the PBMCs by negative selection. To assess the direct cytotoxicity and IFN-γ production capability of NK cells, co-cultured with uninfected, HCV-infected, HCV-NS3 DNA - transfected Huh-7.5, or HCV-NS replicon cells. To determine the effect of an NS3 serine protease inhibitor, HCV -infected Huh-7.5 cells were treated with BILN-2061. Then, NK cells were harvested and further co-cultured with K-562 target cells. NK cell functions were analyzed by flow cytometry and enzyme-linked immunosorbent assay. When co-cultured with HCV-infected Huh-7.5 cells, the natural cytotoxicity and IFN-γ production capability of NK cells were significantly reduced. NK cell functions were inhibited to similar levels upon co-culture with HCV-NS replicon cells, NS3 - transfected cells, and HCV-infected Huh-7.5 cells. These reductions were restored by BILN-2061 - treatment. Furthermore, BILN-2061 - treatment significantly increased degranulation against K-562 target cells and IFN-γ productivity in NK cells. Consistent with these findings, the expression levels of activating NK cell receptors, such as NKp46 and NKp30, were also increased. In HCV-infected cells, the serine protease NS3 may play a role in the abrogation of NK cell functions in the early phase of infection through downregulation of NKp46 and NKp30 receptors on NK cells. Together, these results suggest that NS3 represents a novel drug target for the treatment of HCV infections.
28410411	0	17	Hepatitis C virus	T005	UMLS:C0220847
28410411	26	54	natural killer cell activity	T038	UMLS:C1317556
28410411	59	84	viral serine protease NS3	T103	UMLS:C2717971
28410411	85	118	Hepatitis C virus (HCV) infection	T038	UMLS:C4288963
28410411	211	236	adaptive immune responses	T038	UMLS:C1155229
28410411	256	290	natural killer (NK) cell functions	T038	UMLS:C1317556
28410411	294	297	HCV	T005	UMLS:C0220847
28410411	390	393	HCV	T005	UMLS:C0220847
28410411	390	402	HCV proteins	T103	UMLS:C0042736
28410411	411	425	immune evasion	T038	UMLS:C1654934
28410411	478	491	HCV infection	T038	UMLS:C4288963
28410411	520	523	HCV	T005	UMLS:C0220847
28410411	520	546	HCV nonstructural proteins	T103	UMLS:C0069065
28410411	558	561	NS3	T103	UMLS:C0249187
28410411	583	595	NK functions	T038	UMLS:C1317556
28410411	597	605	NK cells	T017	UMLS:C0022688
28410411	638	656	negative selection	T058	UMLS:C2347338
28410411	679	691	cytotoxicity	T038	UMLS:C0596402
28410411	696	712	IFN-γ production	T038	UMLS:C1819433
28410411	727	735	NK cells	T017	UMLS:C0022688
28410411	737	748	co-cultured	T058	UMLS:C0282547
28410411	766	778	HCV-infected	T017	UMLS:C0007634
28410411	780	791	HCV-NS3 DNA	T103	UMLS:C0012854
28410411	794	805	transfected	T038	UMLS:C0314641
28410411	806	813	Huh-7.5	T017	UMLS:C0007634
28410411	818	824	HCV-NS	T103	UMLS:C0033684
28410411	825	833	replicon	T103	UMLS:C0035142
28410411	834	839	cells	T017	UMLS:C0007634
28410411	871	874	NS3	T103	UMLS:C0069065
28410411	875	900	serine protease inhibitor	T103	UMLS:C0036733
28410411	902	905	HCV	T005	UMLS:C0220847
28410411	902	915	HCV -infected	T017	UMLS:C0007634
28410411	916	929	Huh-7.5 cells	T017	UMLS:C0007634
28410411	935	947	treated with	T058	UMLS:C0332293
28410411	948	957	BILN-2061	T103	UMLS:C1313841
28410411	965	973	NK cells	T017	UMLS:C0022688
28410411	979	988	harvested	T058	UMLS:C0022885
28410411	1001	1012	co-cultured	T058	UMLS:C0282547
28410411	1018	1036	K-562 target cells	T017	UMLS:C0600432
28410411	1038	1055	NK cell functions	T038	UMLS:C1317556
28410411	1061	1069	analyzed	T062	UMLS:C0936012
28410411	1073	1087	flow cytometry	T058	UMLS:C0016263
28410411	1092	1125	enzyme-linked immunosorbent assay	T058	UMLS:C0014441
28410411	1132	1143	co-cultured	T058	UMLS:C0282547
28410411	1149	1161	HCV-infected	T038	UMLS:C4288963
28410411	1162	1175	Huh-7.5 cells	T017	UMLS:C0007634
28410411	1189	1201	cytotoxicity	T038	UMLS:C0596402
28410411	1206	1222	IFN-γ production	T038	UMLS:C1819433
28410411	1237	1245	NK cells	T017	UMLS:C0022688
28410411	1274	1291	NK cell functions	T038	UMLS:C1317556
28410411	1330	1340	co-culture	T058	UMLS:C0282547
28410411	1346	1352	HCV-NS	T103	UMLS:C0033684
28410411	1353	1361	replicon	T103	UMLS:C0035142
28410411	1362	1367	cells	T017	UMLS:C0007634
28410411	1369	1372	NS3	T103	UMLS:C0069065
28410411	1375	1386	transfected	T038	UMLS:C0314641
28410411	1387	1392	cells	T017	UMLS:C0007634
28410411	1398	1410	HCV-infected	T038	UMLS:C4288963
28410411	1411	1424	Huh-7.5 cells	T017	UMLS:C0007634
28410411	1460	1469	BILN-2061	T103	UMLS:C1313841
28410411	1496	1505	BILN-2061	T103	UMLS:C1313841
28410411	1542	1555	degranulation	T038	UMLS:C0007588
28410411	1564	1582	K-562 target cells	T017	UMLS:C0600432
28410411	1587	1605	IFN-γ productivity	T038	UMLS:C1819433
28410411	1609	1617	NK cells	T017	UMLS:C0022688
28410411	1641	1649	findings	T033	UMLS:C0243095
28410411	1687	1704	NK cell receptors	T103	UMLS:C2350463
28410411	1714	1719	NKp46	T103	UMLS:C2757033
28410411	1724	1729	NKp30	T103	UMLS:C2757035
28410411	1755	1767	HCV-infected	T038	UMLS:C4288963
28410411	1768	1773	cells	T017	UMLS:C0007634
28410411	1779	1798	serine protease NS3	T103	UMLS:C2717971
28410411	1836	1853	NK cell functions	T038	UMLS:C1317556
28410411	1876	1885	infection	T038	UMLS:C3714514
28410411	1894	1908	downregulation	T038	UMLS:C0013081
28410411	1912	1917	NKp46	T103	UMLS:C2757033
28410411	1922	1937	NKp30 receptors	T103	UMLS:C2757035
28410411	1941	1949	NK cells	T017	UMLS:C0022688
28410411	1988	1991	NS3	T103	UMLS:C0069065
28410411	2011	2022	drug target	T074	UMLS:C0085104
28410411	2044	2058	HCV infections	T038	UMLS:C4288963